Clinical Trials Browser

Phase 2 × Completed × pembrolizumab × Clear all

NCT02818920 2026-03-17

TOP 1501

Phase 2 Completed

35 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Phase 2 Completed

378 enrolled 15 charts 1 FDA

Uveal Melanoma, Melanoma

NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Phase 2 Completed

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02648282 2026-03-13

Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer

Phase 2 Completed

58 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03322267 2026-03-06

Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence

Phase 2 Completed

26 enrolled 6 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03519412 2026-03-03

ARETHUSA

Phase 2 Completed

107 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms, Microsatellite Instability

NCT05005442 2026-02-19

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Phase 2 Completed

192 enrolled 22 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT03480672 2026-02-17

Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT02362997 2026-02-12

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Phase 2 Completed

82 enrolled 20 charts

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Phase 2 Completed

7 enrolled 14 charts

GastrointestinalHead & Neck

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02964078 2026-02-10

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2 Completed

27 enrolled 10 charts

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT03025035 2026-02-06

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Phase 2 Completed

14 enrolled 8 charts

Breast Neoplasms

NCT03727880 2026-02-04

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Phase 2 Completed

28 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03204188 2026-01-30

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2 Completed

15 enrolled 9 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT03264404 2026-01-27

Azacitidine and Pembrolizumab in Pancreatic Cancer

Phase 2 Completed

36 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03752333 2026-01-22

CUPem

Phase 2 Completed

Neoplasms, Unknown Primary

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03210662 2026-01-13

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 2 Completed

17 enrolled 9 charts

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

NCT03873818 2026-01-09

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

Phase 2 Completed

24 enrolled 13 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04227509 2025-12-31

Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Phase 2 Completed

Nasopharyngeal Carcinoma

NCT03095352 2025-12-22

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Phase 2 Completed

76 enrolled 14 charts

Breast Neoplasms

NCT04798781 2025-12-11

Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

Phase 2 Completed

16 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular, Stomach Neoplasms

NCT04811027 2025-12-11

TACTI-003

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT03007732 2025-12-05

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Phase 2 Completed

23 enrolled 14 charts

Prostatic Neoplasms

NCT02921256 2025-12-04

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Phase 2 Completed

363 enrolled 16 charts

Gastrointestinal

Rectal Neoplasms

NCT04428151 2025-12-04

LEAP-009

Phase 2 Completed

408 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT04704219 2025-12-03

KEYNOTE-B61

Phase 2 Completed

160 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04165083 2025-11-26

MK-3475-01B

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04570332 2025-11-26

SPOTLIGHT203

Phase 2 Completed

42 enrolled 12 charts

Melanoma

NCT02625961 2025-11-21

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Phase 2 Completed

Urinary Bladder Neoplasms

NCT04796194 2025-11-20

ATLAS-IT-05

Phase 2 Completed

Melanoma

NCT04454489 2025-11-19

Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

Phase 2 Completed

21 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck

NCT05052723 2025-11-19

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Phase 2 Completed

21 enrolled 12 charts

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT03984578 2025-11-18

Window of Opportunity Study in Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT04828486 2025-11-18

Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

Phase 2 Completed

14 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT02316002 2025-11-06

Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer

Phase 2 Completed

51 enrolled 7 charts

Oligometastatic Non-small Cell Lung Cancer (NSCLC)

NCT04875195 2025-10-29

MK-3475-B68

Phase 2 Completed

66 enrolled 16 charts

Hodgkin Disease

NCT02882282 2025-10-23

Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

Phase 2 Completed

15 enrolled 8 charts

Mouth Neoplasms

NCT03049618 2025-10-22

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Phase 2 Completed

42 enrolled 40 charts

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT04260126 2025-10-01

VERSATILE002

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05446870 2025-10-01

MK-4830-002

Phase 2 Completed

160 enrolled 19 charts

Ovarian Neoplasms

NCT05271604 2025-09-26

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03184571 2025-09-25

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

99 enrolled 20 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT04768686 2025-09-25

FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer

Phase 2 Completed

20 enrolled 14 charts

Gastrointestinal

Stomach Neoplasms

NCT05104567 2025-09-24

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

Phase 2 Completed

138 enrolled 32 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Carcinoma, Hepatocellular, Stomach Neoplasms, Colorectal Neoplasms

NCT04383743 2025-09-18

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

Phase 2 Completed

17 enrolled 12 charts

Urinary Bladder Neoplasms

NCT02973997 2025-08-29

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Phase 2 Completed

57 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT03899805 2025-08-28

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Phase 2 Completed

57 enrolled 14 charts

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT03322540 2025-08-22

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Phase 2 Completed

154 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms